Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Mecasermin rinfabate by Chiesi Farmaceutici for Bronchopulmonary Dysplasia: Likelihood of Approval
Mecasermin rinfabate is under clinical development by Chiesi Farmaceutici and currently in Phase II for Bronchopulmonary Dysplasia. According to GlobalData,...
Tanimilast by Chiesi Farmaceutici for Chronic Bronchitis: Likelihood of Approval
Tanimilast is under clinical development by Chiesi Farmaceutici and currently in Phase III for Chronic Bronchitis. According to GlobalData, Phase...
Tanimilast by Chiesi Farmaceutici for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
Tanimilast is under clinical development by Chiesi Farmaceutici and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According...
Tanimilast by Chiesi Farmaceutici for Asthma: Likelihood of Approval
Tanimilast is under clinical development by Chiesi Farmaceutici and currently in Phase II for Asthma. According to GlobalData, Phase II...
CHF-6333 by Chiesi Farmaceutici for Cystic Fibrosis: Likelihood of Approval
CHF-6333 is under clinical development by Chiesi Farmaceutici and currently in Phase I for Cystic Fibrosis. According to GlobalData, Phase...
Deferiprone by Chiesi Farmaceutici for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
Deferiprone is under clinical development by Chiesi Farmaceutici and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS)....
CHF-6333 by Chiesi Farmaceutici for Bronchiectasis: Likelihood of Approval
CHF-6333 is under clinical development by Chiesi Farmaceutici and currently in Phase II for Bronchiectasis. According to GlobalData, Phase II...
Birch triterpenes by Chiesi Farmaceutici for Radiodermatitis: Likelihood of Approval
Birch triterpenes is under clinical development by Chiesi Farmaceutici and currently in Phase II for Radiodermatitis. According to GlobalData, Phase...